Samsung Biologics Inks CDMO Deal with Enzolytics on HIV and COVID-19 Antibodies
U.S.-based Enzolytics this week inked a deal with one of the world’s biggest CDMO firms. Samsung Biologics will help develop and manufacture Enzolytics’s HIV and SARS-CoV-2 targeting monoclonal antibodies to accelerate the latter’s IND filing process.
Provide End-to-End CDMO Service
The Korean firm will provide services involving the development and manufacture of cell lines and clinical drug products. Their R&D Center located in San Francisco will manufacture a stable cell line while the Incheon headquarters will produce related trial materials.
“We chose to partner with Samsung Biologics because of Samsung Biologics’ extensive experience and expertise in developing, producing, and manufacturing Monoclonal Antibodies for Infectious Diseases and Oncology,” said Dr. Gaurav Chandra, Enzolytics’ Chief Operating Officer Research and Development.
“This partnership marks a pivotal milestone for Enzolytics to significantly advance the clinical development of our universal, durable, broadly neutralizing Monoclonal Antibodies and reduce time to the clinic and offer the much-needed treatment for patients.”
The pair might advance the collaboration to include other products from Enzolytics.
Use AI to Develop Antibodies for Infectious Diseases
Enzolytics will carry out AI analysis to develop antibodies that target immutable locations on viruses that cause infectious diseases. Their antibody development on HIV therapeutics is the most advanced among all the indications. ITV-1, Enzolytics’s HIV therapeutics, is currently on trial in the EU.
The firm is also developing treatments for rheumatoid arthritis, influenza A and B, tetanus, and hepatitis (A, B, C). Now, their technology is also implemented in developing antibodies against the COVID-19 virus.©www.geneonline.com All rights reserved. Collaborate with us: firstname.lastname@example.org